Stocks and Investing
Stocks and Investing
Fri, July 16, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Matthew Harrison Maintained (BIIB) at Buy with Decreased Target to $453 on, Jul 16th, 2021
Matthew Harrison of Morgan Stanley, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $455 to $453 on, Jul 16th, 2021.
Matthew has made no other calls on BIIB in the last 4 months.
There are 15 other peers that have a rating on BIIB. Out of the 15 peers that are also analyzing BIIB, 6 agree with Matthew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $354 on, Monday, June 28th, 2021
- Terence Flynn of "Goldman Sachs" Maintained at Hold with Increased Target to $436 on, Monday, June 14th, 2021
- Mohit Bansal of "Citigroup" Upgraded from Strong Sell to Hold and Increased Target to $440 on, Tuesday, June 8th, 2021
- Brian Skorney of "Baird" Upgraded from Sell to Hold and Increased Target to $382 on, Tuesday, June 8th, 2021
- Carter Gould of "Barclays" Maintained at Hold with Increased Target to $395 on, Tuesday, June 8th, 2021
- Laura Chico of "Wedbush" Maintained at Hold with Increased Target to $245 on, Monday, April 12th, 2021
These are the ratings of the 9 analyists that currently disagree with Matthew
- Christopher Raymond of "Piper Sandler" Upgraded from Hold to Buy and Increased Target to $450 on, Friday, June 18th, 2021
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $647 on, Monday, June 14th, 2021
- Aaron Gal of "Bernstein" Upgraded from Hold to Buy and Held Target at $500 on, Friday, June 11th, 2021
- Colin Bristow of "UBS" Upgraded from Hold to Strong Buy and Held Target at $463 on, Thursday, June 10th, 2021
- Marc Goodman of "SVB Leerink" Maintained at Buy with Increased Target to $475 on, Thursday, June 10th, 2021
- Matt Phipps of "William Blair" Upgraded from Hold to Buy on, Tuesday, June 8th, 2021
- Michael Yee of "Jefferies" Maintained at Strong Buy with Increased Target to $500 on, Tuesday, June 8th, 2021
- Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Increased Target to $452 on, Tuesday, June 8th, 2021
- Jay Olson of "Oppenheimer" Maintained at Buy with Increased Target to $325 on, Tuesday, May 18th, 2021
Contributing Sources